Arizona State Retirement System’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-16,410
Closed -$2.48M 2309
2022
Q3
$2.48M Buy
16,410
+165
+1% +$24.5K 0.03% 549
2022
Q2
$2.37M Buy
16,245
+310
+2% +$39.6K 0.02% 565
2022
Q1
$1.89M Buy
15,935
+93
+0.6% +$11.6K 0.02% 744
2021
Q4
$2.18M Sell
15,842
-111
-0.7% -$14.1K 0.02% 694
2021
Q3
$2.22M Buy
15,953
+1,289
+9% +$161K 0.02% 675
2021
Q2
$1.42M Sell
14,664
-167
-1% -$13.6K 0.01% 903
2021
Q1
$1.01M Buy
14,831
+118
+0.8% +$9.54K 0.01% 1102
2020
Q4
$1.26M Sell
14,713
-299
-2% -$25.3K 0.01% 908
2020
Q3
$976K Buy
15,012
+3,830
+34% +$251K 0.01% 937
2020
Q2
$818K Buy
11,182
+757
+7% +$40.3K 0.01% 859
2020
Q1
$355K Buy
+10,425
New +$477K 0.01% 1184

Other funds holding BHVN

Arizona State Retirement System's BHVN Position: Q4 2022 in Review

Arizona State Retirement System sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 16,410 shares — an estimated $2.48M sold.

Arizona State Retirement System first reported a position in BHVN in Q1 2020 and held it in 11 quarters. The position peaked at $2.48M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Arizona State Retirement System reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Arizona State Retirement System sold 16,410 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $2.48M.
  • Arizona State Retirement System first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 11 quarters.
  • Arizona State Retirement System's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.48M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Arizona State Retirement System's 13F filing for Q4 2022, filed 8 Feb 2023.